Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase®

Drug Safety

Volumn 39, Issue 1, 2016, Pages 69-78

  Aldea Perona, Ana ^a   García Sáiz, Mar ^a   Sanz Álvarez, Emilio ^b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CETIRIZINE; FLUTICASONE; MOMETASONE FUROATE; MONTELUKAST; PROPIONIC ACID; SALBUTAMOL; SALMETEROL; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; QUINOLINE DERIVATIVE;

ANXIETY; ARTICLE; AUTOMUTILATION; CHILD; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; NIGHTMARE; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT DURATION; ADOLESCENT; AGE; BAYES THEOREM; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; INFANT; MENTAL DISORDERS; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; SUICIDE;

ACETATES; ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; ANTI-ASTHMATIC AGENTS; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENTAL DISORDERS; PHARMACOVIGILANCE; QUINOLINES; RETROSPECTIVE STUDIES; SUICIDE;

EID: 84954380236     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0360-2     Document Type: Article

References (36)

1. FDA. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). Postmarketed drug safety information for patients and providers, 8/28/2009 [online]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm165489.htm. Accessed 30 Jan 2014.
2. FDA. Follow-up to the March 27, 2008 communication about the ongoing safety review of montelukast (Singulair) Postmarketed drug safety information for patients and providers, 1/13/2009 [online]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients. Accessed 16 Jan 2014.
3. Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J Allergy Clin Immunol. 2008;122(4):828–9. doi:10.1016/j.jaci.2008.07.012.
4. Kelsay K. Assessing risk: Data from montelukast clinical trials. J Allergy Clin Immunol. 2009;124(4):697–8. doi:10.1016/j.jaci.2009.09.001.
5. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):699–706.e8. doi:10.1016/j.jaci.2009.08.011. (Erratum in: J Allergy Clin Immunol. 2010 May;125(5):1019).
6. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):691–6.e6. doi:10.1016/j.jaci.2009.08.010.
7. Food and Drug Administration. Highlights of Prescribing Information (Singulair), 11/2014. [online]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020829Orig1s068,020830Orig1s070,021409Orig1s045lbl.pdf. Accessed 28 Sept 2015.
8. AEMPS. [internet]. Madrid: Centro de Información online de Medicamentos de la AEMPS; 2015 [cited 2015 Sep 28]. Available from: http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm.
9. ANSM. [internet]. Saint-Denis Cedex: Base de données publique des médicaments; 2015 [cited 2015 Sep 28]. Available form: http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63842168.
10. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009;18(9):858–64. doi:10.1002/pds.1794.
11. Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol Drug Saf. 2012;21(1):79–86. doi:10.1002/pds.2265.
12. Marchand MS, Jonville-Béra AP. Autret-Leca E; Association française des centres régionaux de pharmacovigilance. [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. Arch Pediatr. 2013;20(3):269–73. doi:10.1016/j.arcped.2012.12.006.
13. Aldea-Perona A, Fernández-quintana E, García Sánchez-Colomer M. Up-to-date of the neuropsychiatric events in relation with antileukotriens-agents in the spanish surveillance system (SISTEMA ESPAÑOL DE FARMACOVIGILANCIA-SEFV). In: Kim Brøsen, editor. Basic and clinical pharmacology and toxicology: Abstracts for the XXIV Conference of the Spanish Society of Clinical Pharmacology, Translating Science to the Art of Therapeutics, 5–7 October 2011, Málaga, Spain. Basic and Clinical Pharmacology and Toxicology: 2011;109(Suppl 3):32–40.
14. WHO [internet]. Uppsala: Uppsala Monitoring Center. 2015 [cited 2015 September 28]. Available from: http://www.who-umc.org/DynPage.aspx?id=98080&mn1=7347&mn2=7252&mn3=7322&mn4=7324.
15. WHO [internet]. Uppsala: Uppsala Monitoring Center 2015 [cited 2015 May 27]. Avalilable from: http://www.who-umc.org/DynPage.aspx?id=98082&mn1=7347&mn2=7252&mn3=7322&mn4=7326.
16. CPMP.[internet]. London: European Medicines Agency [cited 2014 January 16] Clinical Investigation of Medicinal Products in the Paediatric Population. CPMP/ICH/2711/99. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf.
17. ICH [internet]. Geneve: IFPMA [cited 2015 March] Introductory guide MedDRA version 18.0. Available from: http://www.meddra.org/sites/default/files/guidance/file/intguide_18_0_english.pdf.
18. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–21.
19. Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393–7.
20. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69. doi:10.1177/0962280211403604.
21. WHO [internet]. Uppsala: Uppsala Monitoring Center [cited 2015 September 22]. Available from: http://www.who-umc.org/graphics/25300.pdf.
22. Meyboom RH, Lindquist M, Egberts AC, Edwards IR. Signal selection and follow-up in pharmacovigilance. Drug Saf. 2002;25(6):459–65.
23. Novak M, Shapiro CM. Drug-induced sleep disturbances. Focus on nonpsychotropic medications. Drug Saf. 1997;16(2):133–49.
24. Goodwin RD, Bandiera FC, Steinberg D, Ortega AN, Feldman JM. Asthma and mental health among youth: etiology, current knowledge and future directions. Expert Rev Respir Med. 2012;6(4):397–406. doi:10.1586/ers.12.34.
25. Goodwin RD, Fergusson DM, Horwood LJ. Asthma and depressive and anxiety disorders among young persons in the community. Psychol Med. 2004;34(8):1465–74.
26. Bolton JM, Walld R, Chateau D, Finlayson G, Sareen J. Risk of suicide and suicide attempts associated with physical disorders: a population-based, balancing score-matched analysis. Psychol Med. 2015;45(3):495–504. doi:10.1017/S0033291714001639.
27. Kuo CJ, Chen VC, Lee WC, Chen WJ, Ferri CP, Stewart R, Lai TJ, Chen CC, Wang TN, Ko YC. Asthma and suicide mortality in young people: a 12-year follow-up study. Am J Psychiatry. 2010;167(9):1092–9. doi:10.1176/appi.ajp.2010.09101455.
28. Goodwin RD, Marusic A. Asthma and suicidal ideation among youth in the community. Crisis. 2004;25(3):99–102.
29. Iessa N, Murray ML, Curran S, Wong IC. Asthma and suicide-related adverse events: a review of observational studies. Eur Respir Rev. 2011;20(122):287–92. doi:10.1183/09059180.00005211.
30. de Boissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Dramé M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2014;23(9):989–92. doi:10.1002/pds.3622.
31. Manalai P, Woo JM, Postolache TT. Suicidality and montelukast. Expert Opin Drug Saf. 2009;8(3):273–82. doi:10.1517/14740330902932688.
32. US Department of Health and Human Services [internet]. Silver Spring: US Food and Drug Administration, 2015. [cited 2014 September 2] Pediatric postmarketing pharmacovigilance and drug utilization review. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM414065.pdf.
33. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357(18):1841–54.
34. Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010;85(6):336–49. doi:10.1159/000312669.
35. Ibáñez C, Pedrós C, Maciá MA, Torelló J, Madruga M. Procedimientos de trabajo para la generación de señales en el Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano. In: Universidad de Oviedo, editor. Los primeros 25 años del sistema español de farmacovigilancia de medicamentos de uso humano. Oviedo; 2010. pp. 145–156.
36. de Boer A. When to publish measures of disproportionality derived from spontaneous reporting databases? Br J Clin Pharmacol. 2011;72(6):909–11. doi:10.1111/j.1365-2125.2011.04087.